When is the patent up on dupilumab?

When does dupilumab’s patent protection end?

Dupilumab (Dupixent) patent timelines depend on which specific patent family you mean (there are multiple patents covering different aspects of the product and formulation). Because of that, the practical “until” date can vary between legal milestones such as expiration of particular patents and any extensions or exclusivities tied to regulatory approval.

To check the most up-to-date, patent-by-patent expiration information for dupilumab, see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/dupixent-davilumab

Is there a single “final” patent expiry date for Dupixent?

There usually isn’t one universal date. For drugs like dupilumab, different patents expire at different times depending on:
- the patent’s filing and grant dates,
- whether any patent term adjustments/extensions apply,
- which claim is asserted (method of use, formulation, specific biological attributes, etc.),
- the country/jurisdiction you care about.

That is why patent trackers typically list multiple expiration dates rather than one.

Why might the answer differ depending on where you live or how you define “patent up”?

Users often mean one of these:
- The last patent in a relevant family expires (hardest barrier for generic/biosimilar entry).
- The earliest patent that could block an application expires.
- The date exclusivity ends (regulatory protection can extend beyond or alongside patents).

These can land on different calendars, especially across the US vs. Europe and across different patent types.

Sources cited

1. DrugPatentWatch.com – Dupixent (dupilumab) patent information